Evidence map›Paper›PMID 34830395›Full record

ArticleInternational journal of molecular sciences2021

Characterizing the NLRP3 Inflammasome in Mood Disorders: Overview, Technical Development, and Measures of Peripheral Activation in Adolescent Patients.

Xinyang Zhou, Shehan M Fernando, Alexander Y Pan, Rebecca Laposa, Kathryn R Cullen, Bonnie Klimes-Dougan, Ana C Andreazza

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The relationship between neurodevelopmental disorders (NDDs) and NLRP3 inflammasome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  6. Review
  7. Review
  8. Biology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The NLRP3-Inflammasome in Health and Disease.International journal of molecular sciences · 2022
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xinyang ZhouDepartment of Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0002-1836-5222
Shehan M FernandoDepartment of Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Alexander Y PanDepartment of Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Rebecca LaposaDepartment of Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Kathryn R CullenDepartment of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN 55454, USA.
Bonnie Klimes-DouganDepartment of Psychology, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-2107-0038
Ana C AndreazzaDepartment of Pharmacology, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0002-4323-7273
University of Toronto · CAUniversity of Minnesota · US

Funding

Early Research Award ERA14-10-022Ontario Mental Health Foundation 498567University of Toronto Neuroscience Catalyst
6 · The paper itself

Abstract

The NOD-, LRR-, and pyrin-domain-containing protein 3 (NLRP3) inflammasome is a node of intracellular stress pathways and a druggable target which integrates mitochondrial stress and inflammatory cascades. While a body of evidence suggests the involvement of the NLRP3 inflammasome in numerous diseases, a lack of reliable measurement techniques highlights the need for a robust assay using small quantities of biological samples. We present a literature overview on peripheral activation of the NLRP3 inflammasome in mood disorders, then outline a process to develop and validate a robust assay to measure baseline and activated intracellular levels of "apoptosis-associated speck-like protein containing a CARD" (ASC) as a key component of an inflammatory profile in peripheral blood mononuclear cells (PBMC). A consistent association between high NLRP3 mRNA levels and relevant cytokines was seen in the literature. Using our method to measure ASC, stimulation of PBMC with lipopolysaccharide and nigericin or adenosine triphosphate resulted in microscopic identification of intracellular ASC specks, as well as interleukin 1 (IL-1) beta and caspase-1 p10 in the periphery. This was abolished by dose-dependent pre-treatment with 100 nM MCC950. We also report the use of this technique in a small pilot sample from patients with bipolar disorder and depressive disorders. The results show that levels of intracellular ASC and IL-1 beta are sensitive to change upon activation and maintained over time, which may be used to improve the detection of NLRP3 activation and guide personalized therapeutic strategy in the treatment of patients.

Indexed as

AdolescentAnimalsApoptosisCARD Signaling Adaptor ProteinsCaspase 1FemaleHumansInflammasomesInflammationInterleukin-1betaLeukocytes, MononuclearMaleMitochondriaMood DisordersNLR Family, Pyrin Domain-Containing 3 ProteinCARD Signaling Adaptor ProteinsCaspase 1InflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanPYCARD protein, humanASC specksbipolardepressionIL-1 betainflammationNLRP3

Identifiers

PMID34830395
PMCPMC8618969
OpenAlexW3217622676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.